Ignite Creation Date:
2025-12-25 @ 1:12 AM
Ignite Modification Date:
2025-12-29 @ 9:43 AM
Study NCT ID:
NCT02277093
Status:
TERMINATED
Last Update Posted:
2017-05-01
First Post:
2014-10-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Sponsor:
Washington University School of Medicine
Organization:
Study Overview
Official Title:
Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Status:
TERMINATED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
FDA issued a clinical hold as pacritinib had increased side effects
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators propose to assess the efficacy, progression-free survival, and adverse events of pacritinib in patients with refractory colorectal cancer.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: